Resolution of statin-induced myalgia by correcting vitamin D deficiency: a case report

Luca Gallelli, Andzelika Michniewicz, Antonio Siniscalchi, Giovambattista De Sarro



The onset of myalgia is a well-known side effect of cholesterol-lowering statins. Recent studiesa dvanced the hypothesis that reduced vitamin D levels may play a role in the onset of myalgia in statin users and potentially a vitamin D supplementation may be useful in these cases, as suggested by the present case report.

A 52-year-old man with a history of smoke and successfully controlled hypertension presented with chest pain and asthenia. He was diagnosed with stable angina pectoris and discharged on atorvastatin. Due to the onset of myalgia, the dosage of atorvastatin was reduced (from 40 mg daily to 20 mg daily) and then atorvastatin was switched to rosuvastatin without symptoms improvement. Switching from rosuvastatin to ezetimibe resulted in pain improvement, but also in plasma lipids increase beyond the normal range. Ezetimibe was switched to rosuvastatin+ analgesic; in the meanwhile a high-performance liquid chromatography (HPLC) analysis showed low levels of 25-hydroxy-vitamin D and 1-25-dihydroxy-vitamin D. Therefore, vitamin D3 was added to rosuvastatin, resulting in pain improvement, decrease of plasma lipids and progressive discontinuation of analgesics. During the follow-up, rosuvastatin was switched to atorvastatin + vitamin D3, with a good control of plasma lipid levels and without the onset of myalgia.


Myalgia; Statin; Vitamin D; Vitamin supplementation

Full Text



  • Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-934;
  • Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-90;
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45;
  • Palleria C, Di Paolo A, Giofrè C, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 2013; 18: 601-10
  • Gallelli L, Ferraro M, Spagnuolo V, et al. Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. Drug Metabol Drug Interact 2009; 24: 83-7;
  • Settergren J, Eiermann B, Mannheimer B. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy–A Nationwide Register Study. PLoS ONE 2013; 8: e69545;
  • De Vuono A, Palleria C, Scicchitano F, et al. Skin rash during treatment with generic itraconazole. J Pharmacol Pharmacother 2014; 5: 158-60;
  • Mumoli L, Gambardella A, Labate A, et al. Rosacea-like facial rash related to metformin administration in a young woman. BMC Pharmacol Toxicol 2014; 15: 3;
  • Morioka TY, Lee AJ, Bertisch S, et al. Vitamin D status modifies the association between statin use and musculoskeletal pain: A population based study. Atherosclerosis 2014; 238: 77-82;
  • Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - A systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 2014; 178C: 111-6;
  • Duell PB, Connor WE. Vitamin D deficiency is associatedwith myalgias in hyperlipidemic subjects taking statins. Circulation 2008; 118: 470
  • Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009; 153: 11-6;
  • Bittner V, Wenger NK, Waters DD, et al. Vitamin D levels are not related to myalgias in statin-treated patients with stable coronary disease. J Am Coll Cardiol 2010; 55: 177-1659 (poster contribution);;
  • Mergenhagen K, Ott M, Heckman K, et al. Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review. Clin Ther 2014; 36: 770-7;
  • Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006; 210: 94-102;
  • Pfeifer M, Begerow B, Minne HW. Vitamin D and muscle function. Osteoporos Int 2002; 13: 187-94;
  • Al-Said YA, Al-Rached HS, Al-Qahtani HA, et al. Severe proximal myopathy with remarkable recovery after vitamin D treatment. Can J Neurol Sci 2009; 36: 336-9;
  • Binkley N, Gemar D, Engelke J, et al. Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. J Clin Endocrinol Metab 2011; 96: 981-8;
  • Chaney A. Primary care management of vitamin D deficiency and liver disease. J Am Assoc Nurse Pract 2015 Feb 26 [Epub ahead of print];
  • Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014; 348: g1903;


Abstract: 1094 views
HTML: 1148 views
PDF: 291 views


  • There are currently no refbacks.